Paper40868936
Intersecting Pathways of Inflammation, Oxidative Stress, and Atherogenesis in the Evaluation of CKD: Emerging Biomarkers PCSK9, EPHX2, AOPPs, and TBARSs.
Assani MZ and 6 others. Life (Basel), 2025. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Intersecting Pathways of Inflammation, Oxidative Stress, and Atherogenesis in the Evaluation of CKD: Emerging Biomarkers PCSK9, EPHX2, AOPPs, and TBARSs. Papers, record 40868936. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40868936
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Intersecting Pathways of Inflammation, Oxidative Stress, and Atherogenesis in the Evaluation of CKD: Emerging Biomarkers PCSK9, EPHX2, AOPPs, and TBARSs.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References227
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,222,740 | Oxidative stress during erythropoietin hyporesponsiveness anemia at end stage renal disease: Molecular and biochemical studies. | J Adv Res | 2016 | https://conductscience.org/library/papers/27222740 | PubMed |
| 2 | 23,046,363 | Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. | Nephrology (Carlton) | 2013 | https://conductscience.org/library/papers/23046363 | PubMed |
| 3 | 23,431,388 | A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. | PLoS One | 2013 | https://conductscience.org/library/papers/23431388 | PubMed |
| 4 | 39,682,569 | Correlation Between Prognostic Nutritional Index, Glasgow Prognostic Score, and Different Obesity-Related Indices in People with Diabetes or Prediabetes. | Diagnostics (Basel) | 2024 | https://conductscience.org/library/papers/39682569 | PubMed |
| 5 | 30,934,586 | Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation. | Antioxidants (Basel) | 2019 | https://conductscience.org/library/papers/30934586 | PubMed |
| 6 | 27,562,094 | TNF-α induces vascular insulin resistance via positive modulation of PTEN and decreased Akt/eNOS/NO signaling in high fat diet-fed mice. | Cardiovasc Diabetol | 2016 | https://conductscience.org/library/papers/27562094 | PubMed |
| 7 | 23,761,459 | The Nrf2 pathway in the progression of renal disease. | Nephrol Dial Transplant | 2014 | https://conductscience.org/library/papers/23761459 | PubMed |
| 8 | 34,356,387 | Oxidative Stress in Patients with Advanced CKD and Renal Replacement Therapy: The Key Role of Peripheral Blood Leukocytes. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34356387 | PubMed |
| 9 | 28,804,094 | Lipid Lowering Therapy and Circulating PCSK9 Concentration. | J Atheroscler Thromb | 2017 | https://conductscience.org/library/papers/28804094 | PubMed |
| 10 | 36,755,850 | Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. | Clin Kidney J | 2023 | https://conductscience.org/library/papers/36755850 | PubMed |
| 11 | 36,090,671 | Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. | Lancet Reg Health Eur | 2022 | https://conductscience.org/library/papers/36090671 | PubMed |
| 12 | 26,785,996 | Role of Tyrosine Isomers in Acute and Chronic Diseases Leading to Oxidative Stress - A Review. | Curr Med Chem | 2016 | https://conductscience.org/library/papers/26785996 | PubMed |
| 13 | 23,493,288 | The myeloperoxidase product hypochlorous acid generates irreversible high-density lipoprotein receptor inhibitors. | Arterioscler Thromb Vasc Biol | 2013 | https://conductscience.org/library/papers/23493288 | PubMed |
| 14 | 40,244,241 | The Clinical Utility and Plausibility of Oxidative and Antioxidant Variables in Chronic and End-Stage Kidney Disease: A Review of the Literature. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40244241 | PubMed |
| 15 | 33,525,066 | Role of Inflammation in Arterial Calcification. | Korean Circ J | 2021 | https://conductscience.org/library/papers/33525066 | PubMed |
| 16 | 38,448,299 | Association between CYP4A11 and EPHX2 genetic polymorphisms and chronic kidney disease progression in hypertensive patients. | Nefrologia (Engl Ed) | 2024 | https://conductscience.org/library/papers/38448299 | PubMed |
| 17 | 39,430,292 | Therapy Targeted to the NLRP3 Inflammasome in Chronic Kidney Disease. | Kidney Dis (Basel) | 2024 | https://conductscience.org/library/papers/39430292 | PubMed |
| 18 | 38,523,633 | Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38523633 | PubMed |
| 19 | 38,455,648 | Unveiling the pathogenesis and therapeutic approaches for diabetic nephropathy: insights from panvascular diseases. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38455648 | PubMed |
| 20 | 37,053,275 | Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease. | Circ Res | 2023 | https://conductscience.org/library/papers/37053275 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,921,216 | Shared Tissue-Level Molecular Signatures and Immunometabolic Associations in Nonalcoholic Steatohepatitis and Chronic Kidney Disease: Potential Endothelial Relevance. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42921216 | PubMed |
| 42,626,011 | Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach. | World J Nephrol | 2026 | https://conductscience.org/library/papers/42626011 | PubMed |
| 41,595,770 | Associations of Transforming Growth Factor-β (TGF-β) with Chronic Kidney Disease Progression in Patients Attending a Tertiary Hospital in Johannesburg, South Africa. | Biomedicines | 2026 | https://conductscience.org/library/papers/41595770 | PubMed |
| 41,465,784 | Beyond HOMA-IR: Comparative Evaluation of Insulin Resistance and Anthropometric Indices Across Prediabetes and Type 2 Diabetes Mellitus in Metabolic Syndrome Patients. | Life (Basel) | 2025 | https://conductscience.org/library/papers/41465784 | PubMed |
| 41,154,568 | Stress Pathways in Chronic Kidney Disease: Linking Cortisol, Oxidative Stress, and Inflammation. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/41154568 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EPHX2 | 2,053 | PubTator's text mining | https://conductscience.org/library/genes/2053 | NCBI Gene |
| PCSK9 | 255,738 | PubTator's text mining | https://conductscience.org/library/genes/255738 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40868936
GET https://conductscience.org/api/papers/v1/40868936/references?page=2